索利那新治疗经尿道前列腺电切术后膀胱过度活动症的疗效分析

目的 探讨索利那新治疗经尿道前列腺电切(TURP)术后膀胱过度活动症(OAB)的疗效及安全性.方法 观察64例TURP术后OAB患者拔除尿管当天的排尿情况.根据OAB症状评分(OABSS),按OAB轻、中、重度进行配对后随机分为实验组和对照组,每组各32例.实验组:于拔除尿管后次日起口服索利那新(5 mg,1次/d)2周;对照组:无相关辅助治疗.比较2组拔除尿管后第7、14天的24 h尿急次数、排尿次数、夜尿次数、急迫性尿失禁次数、平均每次尿量、Qmax及OABSS评分.观察实验组治疗期间的不良事件.患者拔除尿管后随访8周.结果 实验组拔管后第7、14天的24 h尿急次数(2.0±1.2,1.1±0.9)、排尿次数(9.7±0.9,7.8±0.9)、夜尿次数(2.2±0.5,1.1±0.6)、急迫性尿失禁次数(0.8±0.7,0.5±0.5)、OABSS评分(7.3±3.1,4.0±2.8)均显著低于对照组的(2.9±1.7,2.2±1.4)、(10.5±1.1,9.6±0.9)、(2.9±0.5,1.8±0.5)、(1.6±1.0,1.1±0.8)、(8.1±3.1,7.6±3.3),2组比较差异均有统计学意义(P均＜0.01);实验组平均每次尿量(183.0±38.3)、(203.2±51.1)ml]显著高于对照组(172.6±35.3)、(178.4±38.2)ml],差异有统计学意义(P＜0.01).实验组在治疗期间不良反应总发生率为12.5%(4/32),但患者均可耐受,未发生严重不良事件.结论 索利那新治疗TURP术后OAB症状安全、有效,可于TURP术后早期应用.

Abstract：

Objective To evaluate the efficacy and safety of solifenacin in the treatment of overactive bladder (OAB) syndrome in patients who have undergone transurethral resection of the prostate (TURP). Methods According to the Overactive Bladder Symptom Score (OABSS), 64 cases with OAB symptoms after TURP were randomly assigned into study and control groups with 32 cases in each group. Patients in the study group were treated with solifenacin (5 mg once daily) for a two week period beginning the first day after catheter removal. Patients in the control group were not treated with solifenacin. The mean urgency episodes, micturition episodes, nocturia, urge incontinence, volume voided per micturition, Qmax and OABSS scores were recorded on the 7th and the 14th day after catheter removal. Treatment-emergent adverse events with solifenacin in the study group were recorded and evaluated as well. All cases were followed-up for 8 weeks after catheter removal. Results There were statistically significant differences (P<0.01) in favor of the study group over the control group in the aspect of urgency, micturition episodes, nocturia, urge incontinence, volume voided per micturition and OABSS scores. The incidences of treatment related adverse events were 12.5% (4/32) in the study group with no serious adverse event observed. Conclusions Solifenacin is effective in the treatment of OAB syndrome after TURP and is well tolerated as well. Application of solifenacin should be recommended earlier after TURP.

Efficacy of Solifenacin in the treatment of overactive bladder syndrome after transurethral resection of the prostate

Objective To evaluate the efficacy and safety of solifenacin in the treatment of overactive bladder (OAB) syndrome in patients who have undergone transurethral resection of the prostate (TURP). Methods According to the Overactive Bladder Symptom Score (OABSS), 64 cases with OAB symptoms after TURP were randomly assigned into study and control groups with 32 cases in each group. Patients in the study group were treated with solifenacin (5 mg once daily) for a two week period beginning the first day after catheter removal. Patients in the control group were not treated with solifenacin. The mean urgency episodes, micturition episodes, nocturia, urge incontinence, volume voided per micturition, Qmax and OABSS scores were recorded on the 7th and the 14th day after catheter removal. Treatment-emergent adverse events with solifenacin in the study group were recorded and evaluated as well. All cases were followed-up for 8 weeks after catheter removal. Results There were statistically significant differences (P<0.01) in favor of the study group over the control group in the aspect of urgency, micturition episodes, nocturia, urge incontinence, volume voided per micturition and OABSS scores. The incidences of treatment related adverse events were 12.5% (4/32) in the study group with no serious adverse event observed. Conclusions Solifenacin is effective in the treatment of OAB syndrome after TURP and is well tolerated as well. Application of solifenacin should be recommended earlier after TURP.